Market Closed - Nyse 04:00:02 2024-03-01 pm EST 5-day change 1st Jan Change
43.45 USD +1.54% Intraday chart for Qiagen N.V. -0.84% -2.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
QIAGEN NV : UBS reaffirms its Neutral rating ZD
Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51 MT
QIAGEN NV : Berenberg reiterates its Buy rating ZD
QIAGEN NV : Deutsche Bank remains its Buy rating ZD
Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep CI
QIAGEN NV : JP Morgan reiterates its Buy rating ZD
QIAGEN NV : UBS reiterates its Neutral rating ZD
QIAGEN : In line Q4; routine business prospects remain intact Alphavalue
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15 DP
Sector Update: Health Care Stocks Mixed Premarket Wednesday MT
Transcript : Qiagen N.V., Q4 2023 Earnings Call, Feb 07, 2024
QIAGEN NV : Gets a Neutral rating from UBS ZD
QIAGEN NV : Berenberg reaffirms its Buy rating ZD
QIAGEN NV : DZ Bank gives a Buy rating ZD
QIAGEN NV : Deutsche Bank reiterates its Buy rating ZD
Qiagen Q4 Adjusted Earnings, Sales Rise; 2024 Outlook Issued, Shares Slump MT
Qiagen N.V. Provides Earnings Guidance for Year 2024 CI
Qiagen N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Qiagen N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
BofA Securities Raises Price Target on Qiagen to $55 From $52, Maintains Buy Rating MT
QIAGEN NV : Buy rating from Deutsche Bank ZD
Qiagen, Pennsylvania State University to Establish Microbiome Research, Education Facility MT
QIAGEN Announces Collaboration with Penn State University in United States to Create Shared Research and Education Facility for Fast-Developing Microbiome Sciences CI
Qiagen Sets Terms for Synthetic Share Repurchase of Up to $300 Million MT
Dpa-AFX Overview: COMPANIES from 19.01.2024 - 15:15 DP
Chart Qiagen N.V.
More charts
Qiagen N.V. is one of the world's leaders in designing, manufacturing, and marketing chemical products for the isolation, purification, and manipulation of DNA (deoxyribonucleic acid) and RNA (ribonucleic acid). In 2022, the group developed more than 500 core consumable products and automated solutions through its over 35 locations worldwide. Net sales are distributed geographically as follows: Europe/Middle East/Africa (34.2%), the United States (42.5%), America (4.1%) and other (19.2%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
43.45 USD
Average target price
51 USD
Spread / Average Target
+17.38%
Consensus
  1. Stock
  2. Equities
  3. Stock Qiagen N.V. - Nyse
  4. News Qiagen N.V.
  5. Qiagen, Myriad Genetics Sign Collaboration Deal for Cancer Diagnostic Tests
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW